|
業務類別
|
Biotechnology |
|
業務概覽
|
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases. |
| 公司地址
| 10 Court Street, P.O. Box 274, Arlington, MA, USA, 02476 |
| 電話號碼
| +1 781 577-5300 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.eloxxpharma.com |
| 員工數量
| 10 |
| Mr. Daniel E. Geffken, M.B.A. |
Interim Chief Financial Officer and Principal Accounting Officer |
-- |
28/04/2023 |
| Mr. Sumit Aggarwal |
Director, President and Chief Executive Officer |
-- |
28/04/2023 |
|
|
| Mr. Steven D. Rubin |
Independent Director |
28/04/2023 |
| Mr. Tomer Kariv |
Chairman of the Board |
28/04/2023 |
| Mr. Sumit Aggarwal |
Director, President and Chief Executive Officer |
28/04/2023 |
| Dr. Alan Walts |
Independent Director |
28/04/2023 |
| Ms. Lindsay Androski |
Independent Director |
28/04/2023 |
|
|
|
|
